Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Pain and Headache Reports
Erschienen in: Current Pain and Headache Reports 4/2013

01.04.2013 | Trigeminal Autonomic Cephalalgias (M Matharu, Section Editor)

Mechanism of Action of Indomethacin in Indomethacin-Responsive Headaches

verfasst von: Oliver Summ, Stefan Evers

Erschienen in: Current Pain and Headache Reports | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Indomethacin, as a member of the non-steroidal anti-inflammatory drug class, plays a special role in the treatment of headaches. By definition, it is completely efficacious in the treatment of the primary headache disorders paroxysmal hemicrania and hemicrania continua. Therefore, indomethacin is also used as a tool for differential diagnosis in headache clinics. Indomethacin has a clear action as a cyclooxygenase inhibitor. Additional mechanisms and interactions with cell signaling pathways and inflammatory pathways are considered in this article. However, it is not known what mechanism or interaction with pathophysiological mechanisms is the key to indomethacin’s specific pharmacology in headache therapy. Focusing on headache therapy, we summarize the current knowledge of pharmacology, treatment options, and recommendations for the use of indomethacin in primary headaches. New findings from the field of headache research, as well as from Alzheimer’s disease and cancer research on the pharmacological actions of indomethacin and their potential implications on the pathophysiology of indomethacin sensitive headaches, are discussed.
Literatur
1.
Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, et al. EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force. Eur J Neurol. 2009;16(9):968–81.PubMedCrossRef
2.
Bendtsen L, Evers S, Linde M, Mitsikostas DD, Sandrini G, Schoenen J. EFNS guideline on the treatment of tension-type headache—report of an EFNS task force. Eur J Neurol. 2010;17(11):1318–25.PubMed
3.
May A, Leone M, Afra J, Linde M, Sandor PS, Evers S, et al. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. Eur J Neurol. 2006;13(10):1066–77.PubMedCrossRef
4.
Headache Classification Committee of the International Headache Society. The international classification of headache disorders: 2nd edition. Cephalalgia. 2004;24 Suppl 1:9–160.
5.
• Evers S, Goadsby P, Jensen R, May A, Pascual J, Sixt G. Treatment of miscellaneous idiopathic headache disorders (Group 4 of the IHS classification)—report of an EFNS task force. Eur J Neurol. 2011;18(6):803–12. A review on therapeutic options of miscellaneous headaches that demonstrates the outstanding role of indomethacin as a treatment option in these headache entities.PubMedCrossRef
6.
Martins IP, Parreira E, Costa I. Extratrigeminal ice-pick status. Headache. 1995;35(2):107–10.PubMedCrossRef
7.
Ammache Z, Graber M, Davis P. Idiopathic stabbing headache associated with monocular visual loss. Arch Neurol. 2000;57(5):745–6.PubMedCrossRef
8.
9.
10.
Mateo I, Pascual J. Coexistence of chronic paroxysmal hemicrania and benign cough headache. Headache. 1999;39(6):437–8.PubMedCrossRef
11.
Diamond S. Prolonged benign exertional headache: its clinical characteristics and response to indomethacin. Headache. 1982;22(3):96–8.PubMedCrossRef
12.
Dodick DW. Indomethacin-responsive headache syndromes. Curr Pain Headache Rep. 2004;8(1):19–26.PubMedCrossRef
13.
Frese A, Rahmann A, Gregor N, Biehl K, Husstedt IW, Evers S. Headache associated with sexual activity: prognosis and treatment options. Cephalalgia. 2007;27(11):1265–70.PubMedCrossRef
14.
Gelfand AA, Goadsby PJ. Primary sex headache in adolescents. Pediatrics. 2012;130(2):e439–41.PubMedCrossRef
15.
Guido M, Specchio LM. Successful treatment of hypnic headache with topiramate: a case report. Headache. 2006;46(7):1205–6.PubMedCrossRef
16.
Pinessi L, Rainero I, Cicolin A, Zibetti M, Gentile S, Mutani R. Hypnic headache syndrome: association of the attacks with REM sleep. Cephalalgia. 2003;23(2):150–4.PubMedCrossRef
17.
Prakash S, Dabhi AS. Relapsing remitting hypnic headache responsive to indomethacin in an adolescent: a case report. J Headache Pain. 2008;9(6):393–5.PubMedCrossRef
18.
Marziniak M, Voss J, Evers S. Hypnic headache successfully treated with botulinum toxin type A. Cephalalgia. 2007;27(9):1082–4.PubMedCrossRef
19.
Martins IP, Gouveia RG. Hypnic headache and travel across time zones: a case report. Cephalalgia. 2001;21(9):928–31.PubMedCrossRef
20.
Ghiotto N, Sances G, Di Lorenzo G, Trucco M, Loi M, Sandrini G, et al. Report of eight new cases of hypnic headache and mini-review of the literature. Funct Neurol. 2002;17(4):211–9.PubMed
21.
Evers S, Rahmann A, Schwaag S, Ludemann P, Husstedt IW. Hypnic headache—the first German cases including polysomnography. Cephalalgia. 2003;23(1):20–3.PubMedCrossRef
22.
Seidel S, Zeitlhofer J, Wober C. First Austrian case of hypnic headache: serial polysomnography and blood pressure monitoring in treatment with indomethacin. Cephalalgia. 2008;28(10):1086–90.PubMedCrossRef
23.
Peters N, Lorenzl S, Fischereder J, Botzel K, Straube A. Hypnic headache: a case presentation including polysomnography. Cephalalgia. 2006;26(1):84–6.PubMedCrossRef
24.
Centonze V, D'Amico D, Usai S, Causarano V, Bassi A, Bussone G. First Italian case of hypnic headache, with literature review and discussion of nosology. Cephalalgia. 2001;21(1):71–4.PubMedCrossRef
25.
Lisotto C, Rossi P, Tassorelli C, Ferrante E, Nappi G. Focus on therapy of hypnic headache. J Headache Pain. 2010;11(4):349–54.PubMedCrossRef
26.
Goadsby PJ, Lipton RB. A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic feature, including new cases. Brain. 1997;120(Pt 1):193–209.PubMedCrossRef
27.
Porta-Etessam J, Cuadrado M, Rodriguez-Gomez O, Garcia-Ptacek S, Valencia C. Are Cox-2 drugs the second line option in indomethacin responsive headaches? J Headache Pain. 2010;11(5):405–7.PubMedCrossRef
28.
Cittadini E, Goadsby PJ. Update on hemicrania continua. Curr Pain Headache Rep. 2011;15(1):51–6.PubMedCrossRef
29.
Morelli N, Mancuso M, Felisati G, Lozza P, Maccari A, Cafforio G, et al. Does sphenopalatine endoscopic ganglion block have an effect in paroxysmal hemicrania? A case report. Cephalalgia. 2010;30(3):365–7.PubMed
30.
•• Akerman S, Holland PR, Summ O, Lasalandra MP, Goadsby PJ. A translational in vivo model of trigeminal autonomic cephalalgias: therapeutic characterization. Brain. 2012;135(Pt 12):3664–75. This article highlights an effect of indomethacin that might arise from interaction with autonomic transmission at the level of the sphenopalatine ganglion and is possibly relevant to the treatment of trigeminoautonomic cephalalgias.PubMedCrossRef
31.
Schoenen J, Jensen RH, Lanteri-Minet M, Lainez MJ, Gaul C, Goodman AM, Caparso A, May A. Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: A randomized, sham-controlled study. Cephalalgia 2013, in press.
32.
Helleberg L. Clinical pharmacokinetics of indomethacin. Clin Pharmacokinet. 1981;6(4):245–58.PubMedCrossRef
33.
Alvan G, Orme M, Bertilsson L, Ekstrand R, Palmer L. Pharmacokinetics of indomethacin. Clin Pharmacol Ther. 1975;18(3):364–73.PubMed
34.
Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest. 2003;112(3):440–9.PubMed
35.
Parepally JM, Mandula H, Smith QR. Brain uptake of nonsteroidal anti-inflammatory drugs: ibuprofen, flurbiprofen, and indomethacin. Pharm Res. 2006;23(5):873–81.PubMedCrossRef
36.
•• Summ O, Andreou AP, Akerman S, Goadsby PJ. A potential nitrergic mechanism of action for indomethacin, but not of other COX inhibitors: relevance to indomethacin-sensitive headaches. J Headache Pain. 2010;11(6):477–83. This article identified an interaction of indomethacin with NO-mechanisms that was not shown by other drugs of the NSAID class. It implicates a possible importance to indomethacin’s mechanism of action in indomethacin-sensitive headaches.PubMedCrossRef
37.
Gierse JK, Koboldt CM, Walker MC, Seibert K, Isakson PC. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J. 1999;339(Pt 3):607–14.PubMedCrossRef
38.
Noreen Y, Ringbom T, Perera P, Danielson H, Bohlin L. Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis. J Nat Prod. 1998;61(1):2–7.PubMedCrossRef
39.
Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A. 1993;90(24):11693–7.PubMedCrossRef
40.
Black WC, Bayly C, Belley M, Chan CC, Charleson S, Denis D, et al. From indomethacin to a selective COX-2 inhibitor: development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett. 1996;6(6):725–30.CrossRef
41.
Kaplan L, Weiss J, Elsbach P. Low concentrations of indomethacin inhibit phospholipase A2 of rabbit polymorphonuclear leukocytes. Proc Natl Acad Sci U S A. 1978;75(6):2955–8.PubMedCrossRef
42.
• Joachim A, Lautscham E, Christoffers J, Ruttkowski B. Oesophagostomum dentatum: effect of glutathione S-transferase (GST) inhibitors on GST activity and larval development. Exp Parasitol. 2011;127(4):762–7. Indomethacins capabilities in gluthation S transferase inhibition were demonstrated.PubMedCrossRef
43.
Hayeshi R, Chinyanga F, Chengedza S, Mukanganyama S. Inhibition of human glutathione transferases by multidrug resistance chemomodulators in vitro. J Enzyme Inhib Med Chem. 2006;21(5):581–7.PubMedCrossRef
44.
Vandenberghe Y, Ratanasavanh D, Glaise D, Guillouzo A. Influence of medium composition and culture conditions on glutathione S-transferase activity in adult rat hepatocytes during culture. In Vitro Cell Dev Biol. 1988;24(4):281–8.PubMedCrossRef
45.
Cerbo R, Centonze V, Grazioli I, Tavolato B, Trenti T, Uslenghi C, et al. Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine in the treatment of episodic tension-type headache: a double-blind, randomized, nimesulide-controlled, parallel group, multicentre trial. Eur J Neurol. 2005;12(10):759–67.PubMedCrossRef
46.
Antonaci F, Pareja JA, Caminero AB, Sjaastad O. Chronic paroxysmal hemicrania and hemicrania continua. Parenteral indomethacin: the 'indotest'. Headache. 1998;38(2):122–8.PubMedCrossRef
47.
Antonaci F, Sandrini G, Danilov A, Sand T. Neurophysiological studies in chronic paroxysmal hemicrania and hemicrania continua. Headache. 1994;34(8):479–83.PubMedCrossRef
48.
Marmura MJ, Silberstein SD, Gupta M. Hemicrania continua: who responds to indomethacin? Cephalalgia. 2009;29(3):300–7.PubMedCrossRef
49.
Cittadini E, Goadsby PJ. Hemicrania continua: a clinical study of 39 patients with diagnostic implications. Brain. 2010;133(Pt 7):1973–86.PubMedCrossRef
50.
Cohen AS, Matharu MS, Goadsby PJ. Trigeminal autonomic cephalalgias: current and future treatments. Headache. 2007;47(6):969–80.PubMedCrossRef
51.
Buzzi MG, Sakas DE, Moskowitz MA. Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater. Eur J Pharmacol. 1989;165(2–3):251–8.PubMedCrossRef
52.
Bakken IJ, Vincent MB, White LR, Cappelen J, Skaanes KO, Sjaastad O. Low concentrations of lithium and cyclooxygenase inhibitors enhance endothelin-1 (ET-1)-induced contractions in human temporal artery, but not in porcine ophthalmic artery. Headache. 1992;32(10):475–9.PubMedCrossRef
53.
Neeb L, Hellen P, Boehnke C, Hoffmann J, Schuh-Hofer S, Dirnagl U, et al. IL-1beta stimulates COX-2 dependent PGE(2) synthesis and CGRP release in rat trigeminal ganglia cells. PLoS One. 2011;6(3):e17360.PubMedCrossRef
54.
Andreou AP, Summ O, Charbit AR, Romero-Reyes M, Goadsby PJ. Animal models of headache: from bedside to bench and back to bedside. Expert Rev Neurother. 2010;10(3):389–411.PubMedCrossRef
55.
Gupta S, Bhatt DK, Boni LJ, Olesen J. Improvement of the closed cranial window model in rats by intracarotid infusion of signalling molecules implicated in migraine. Cephalalgia. 2010;30(1):27–36.PubMed
56.
Akerman S, Williamson DJ, Kaube H, Goadsby PJ. The effect of anti-migraine compounds on nitric oxide-induced dilation of dural meningeal vessels. Eur J Pharmacol. 2002;452(2):223–8.PubMedCrossRef
57.
Sances G, Tassorelli C, Pucci E, Ghiotto N, Sandrini G, Nappi G. Reliability of the nitroglycerin provocative test in the diagnosis of neurovascular headaches. Cephalalgia. 2004;24(2):110–9.PubMedCrossRef
58.
59.
Iversen HK, Olesen J. Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs. Cephalalgia. 1996;16(6):412–8.PubMedCrossRef
60.
Ekbom K. Nitrolglycerin as a provocative agent in cluster headache. Arch Neurol. 1968;19(5):487–93.PubMedCrossRef
61.
62.
May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab. 1999;19(2):115–27.PubMedCrossRef
63.
Strecker T, Dux M, Messlinger K. Increase in meningeal blood flow by nitric oxide—interaction with calcitonin gene-related peptide receptor and prostaglandin synthesis inhibition. Cephalalgia. 2002;22(3):233–41.PubMedCrossRef
64.
Du ZY, Li XY. Inhibitory effects of indomethacin on interleukin-1 and nitric oxide production in rat microglia in vitro. Int J Immunopharmacol. 1999;21(3):219–25.PubMedCrossRef
65.
Jakubowski M, Levy D, Goor-Aryeh I, Collins B, Bajwa Z, Burstein R. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache. 2005;45(7):850–61.PubMedCrossRef
66.
Ghelardini C, Galeotti N, Grazioli I, Uslenghi C. Indomethacin, alone and combined with prochlorperazine and caffeine, but not sumatriptan, abolishes peripheral and central sensitization in in vivo models of migraine. J Pain. 2004;5(8):413–9.PubMedCrossRef
67.
de Groot DJ, van der Deen M, Le TK, Regeling A, de Jong S, de Vries EG. Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1. Br J Cancer. 2007;97(8):1077–83.PubMedCrossRef
68.
Pollard M, Luckert PH. Prolonged antitumor effect of indomethacin on autochthonous intestinal tumors in rats. J Natl Cancer Inst. 1983;70(6):1103–5.PubMed
69.
Roller A, Bahr OR, Streffer J, Winter S, Heneka M, Deininger M, et al. Selective potentiation of drug cytotoxicity by NSAID in human glioma cells: The role of COX-1 and MRP. Biochem Bioph Res Co. 1999;259(3):600–5.CrossRef
70.
Ogino M, Minoura S. Indomethacin increases the cytotoxicity of cis-platinum and 5-fluorouracil in the human uterine cervical cancer cell lines SKG-2 and HKUS by increasing the intracellular uptake of the agents. Int J Clin Oncol. 2001;6(2):84–9.PubMedCrossRef
71.
Morrow CS, Smitherman PK, Diah SK, Schneider E, Townsend AJ. Coordinated action of glutathione S-transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification. Mechanism of GST A1-1- and MRP1-associated resistance to chlorambucil in MCF7 breast carcinoma cells. J Biol Chem. 1998;273(32).
72.
•• Lok HC, Suryo Rahmanto Y, Hawkins CL, Kalinowski DS, Morrow CS, Townsend AJ, et al. Nitric oxide storage and transport in cells are mediated by glutathione S-transferase P1-1 and multidrug resistance protein 1 via dinitrosyl iron complexes. J Biol Chem. 2012;287(1):607–18. This article highlights an interaction of indomethacin with nitric oxide mechanisms, demonstrating an effect of indomethacins on nitric oxide metabolism implicating high relevance to nitric oxide dependent mechanisms, including cell signaling.PubMedCrossRef
73.
Kanno T, Yaguchi T, Nagata T, Shimizu T, Tanaka A, Nishizaki T. Indomethacin enhances learning and memory potential by interacting with CaMKII. J Cell Physiol. 2012;227(3):919–26.PubMedCrossRef
74.
Kanno T, Yaguchi T, Nagata T, Nishizaki T. Indomethacin activates protein kinase C and potentiates alpha7 ACh receptor responses. Cell Physiol Biochem. 2012;29(1–2):189–96.PubMedCrossRef
75.
•• Kanno T, Tsuchiya A, Shimizu T, Tanaka A, Nishizaki T. Novel indomethacin action: selective and direct activation of protein kinase C-epsilon. Cell Physiol Biochem. 2012;30(3):771–7. Protein kinase C-epsilon has been shown being activated by indomethacin.PubMedCrossRef
76.
Rasmussen M. Treatment of elevated intracranial pressure with indomethacin: friend or foe? Acta Anaesthesiol Scand. 2005;49(3):341–50.PubMedCrossRef
77.
Kusumi M, Ishizaki K, Kowa H, Adachi Y, Takeshima T, Sakai F, et al. Glutathione S-transferase polymorphisms: susceptibility to migraine without aura. Eur Neurol. 2003;49(4):218–22.PubMedCrossRef
Metadaten
Titel
Mechanism of Action of Indomethacin in Indomethacin-Responsive Headaches
verfasst von
Oliver Summ
Stefan Evers
Publikationsdatum
01.04.2013
Verlag
Current Science Inc.
Erschienen in
Current Pain and Headache Reports / Ausgabe 4/2013
Print ISSN: 1531-3433
Elektronische ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-013-0327-x

Weitere Artikel der Ausgabe 4/2013

Current Pain and Headache Reports 4/2013 Zur Ausgabe

Trigeminal Autonomic Cephalalgias (M Matharu, Section Editor)

Spinal Cord Stimulation in Cluster Headache

Trigeminal Autonomic Cephalalgias (M Matharu, Section Editor)

Management of Trigeminal Autonomic Cephalalgias in Children and Adolescents

Psychiatric Management of Pain (M Clark, Section Editor)

A Review of the Evidence Regarding Associations Between Attachment Theory and Experimentally Induced Pain

Cancer Pain (DA Marcus, Section Editor)

The Science Behind Animal-Assisted Therapy

Trigeminal Autonomic Cephalalgias (M Matharu, Section Editor)

Occipital Injections for Trigemino-Autonomic Cephalalgias: Evidence and Uncertainties

Cancer Pain (DA Marcus, Section Editor)

Cancer Pain Management: What’s New?

Neu im Fachgebiet AINS

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren
Bildnachweise